作者: Ashley T. Martino , Roland W. Herzog , Ignacio Anegon , Oumeya Adjali
DOI: 10.1007/978-1-61779-370-7_11
关键词:
摘要: Following AAV-based gene transfer, the occurrence of adaptive immune responses specific to vector or transgene product is a major roadblock successful clinical translation. These include antibodies against AAV capsid, which can be neutralizing and therefore prevent ability repeatedly administer vector, CD8(+) cytotoxic T lymphocytes, eliminate transduced cells. In addition, humans may have both humoral cellular preexisting immunity, as result from natural infection with parent virus related serotypes. The need for assays detect measure these anti-capsid in experimental animals profound. Here, ELISPOT, immunocapture (ELISA), neutralization are explained provided detail. Furthermore, such techniques readily adapted monitor quantify therapeutic products encoded by genome.